Takara Bio Announces Start of Clinical Research of Cancer Immunotherapy using RetroNectin(R) Expansion Culture System at Tianjin Cancer Institute & Hospital, China
September 18, 2014     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
 
Takara Bio Announces Start of Clinical Research of Cancer Immunotherapy using RetroNectin(R) Expansion Culture System at Tianjin Cancer Institute & Hospital, China - JCN Newswire
Share:
Takara Bio Announces Start of Clinical Research of Cancer Immunotherapy using RetroNectin(R) Expansion Culture System at Tianjin Cancer Institute & Hospital, China

Tokyo, May 2, 2008 - (IRG) - Takara Bio Inc. (TSE: 4974) has entered into a collaboration agreement with Tianjin Cancer Institute & Hospital, Tianjin Medical University as of October 9, 2007. Under this agreement, Tianjin Cancer Institute & Hospital has started clinical research of cancer immunotherapy by T cell expansion culture system using RetroNectin(R) in China.

Five patients have been enrolled in this clinical research, including two renal cancer, one lung cancer, one liver cancer and one thyroid cancer. Four patients received two cycles of lymphocyte infusion and one patient has finished all three cycles of lymphocyte infusions. Up to now, no severe adverse events were observed and all patients' clinical symptoms were relieved. The size of tumor as measured by CT scan shrank in about half degree in one patient with lung cancer, who received two cycles of infusion. Tianjin Cancer Institute & Hospital will continue the clinical research which will enroll total 20 patients.

Tianjin Cancer Institute & Hospital and Takara Bio plans to present these results jointly in China.

About Takara Bio

Takara Bio Inc. (TSE: 4974) is an innovative biotechnology company based in Shiga, Japan. As a world leader in biotechnology research and development, Takara Bio was the first company to market PCR technology in Japan and is also the developer of the RetroNectin(R) reagent, which is a world-standard in gene therapy protocols. In addition to providing research reagents and equipment to the life science research market, Takara Bio has active research and product development activities in the fields of gene and cell-based therapy, and agricultural biotechnology; and is committed preventing disease and improving the quality of life for all people through the use of biotechnology. Through strategic alliances with other industry leaders, the Company aims to extend its reach around the world. More information is available at http://www.takara-bio.com .

Contact:

Takara Bio Inc.
Corporate Communications 
E-mail: bio-ir@takara-bio.co.jp
 


May 2, 2008
Source: Takara Bio

Takara Bio (TSE: 4974)

From the Japan Corporate News Network
http://www.japancorp.net
Topic: Press release summary


 
CSR Report Download
Annual Reports

  More >>    
Most Popular


About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)